Inventiva: first randomization in China for NATiV3
This randomization triggers a $3 million milestone payment from CTTQ, by which Inventiva is expected to have met the conditions precedent necessary to draw down the second €25 million tranche of the EIB loan.
NATiV3 is a long-term study of lanifibranor in adults with biopsy-proven non-cirrhotic NASH and stage F2/F3 liver fibrosis. The study is taking place in 24 countries and is expected to enroll around 900 patients.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction